Pathogen-Reduced Human Plasma from Japan
Human plasma treated with amotosalen/UVA light to inactivate viruses, bacteria, and parasites while preserving therapeutic proteins. Used for transfusion in immunocompromised patients. HTS 3002.12.00.10 covers this modified human blood plasma.
Duty Rate — Japan → United States
15%
Rate breakdown
9903.04.6215%Pharmaceuticals: patented pharma from JP/EU/KR/CH/LI — 15% floor rate
9903.05.860%Universal product exemption (U.S. note 52(b))
9903.05.900%Articles already subject to Section 232 (steel/aluminum/copper + derivatives, autos + parts, wood, medium/heavy vehicles + parts, semiconductors, patented pharma) — U.S. note 52(f)
Import Tips
• Submit INTERCEPT or similar pathogen reduction system validation data to FDA/CBP
• Label with specific inactivation log reduction claims (e.g
• >5 log HIV) for classification support